Doublet vs triplet combination therapy for multiple myeloma

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD from Oxford University Hospitals NHS Foundation Trust, Oxford, UK provides an overview of the debate between himself and Prof. Keith Stewart from the Mayo Clinic on using doublets vs triplets combinations for multiple myeloma (MM). They used two case studies for their debate and Dr Ramasamy presented data on the doublet combination. Dr Ramasamy found that on a young patient, around 51 years of age at diagnosis, who had relapsed after three years of therapy. In this case, the audience of the presentation was in favor of a three drug combination approach. The second patient was 78 and had neuropathy as a side effect of a previous therapy and a kidney impairment. In this case the audience were more convinced about a two drug data. Dr Ramasamy discusses why it is important for clinicians to consider when to choose doublet treatment options and when to use triplet treatment options. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.

Share this video